CA-TULA-TECHNOLOGY
29.4.2021 09:02:12 CEST | Business Wire | Press release
Tula Technology, Inc. , a leader in propulsion efficiency, reported today at the International Vienna Motor Symposium that their product Dynamic Motor Drive (DMD™) mitigates efficiency losses of electric motors while significantly reducing reliance on rare-earth materials. DMD’s application to electric vehicle motors has the potential to increase range while using less energy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005254/en/
Improving the efficiency of the powertrain is key to reducing the energy consumed by an electric vehicle. Electric motors equipped with rare earth magnets can exceed 90% efficiency at peak performance; however, real-world driving conditions often reduce motor efficiency to approximately 70-85%, far below the peak. The patented DMD pulse density strategy mitigates efficiency losses through improvements in control software. Tula has simulated the DMD concept and projects efficiency improvements of 2.5% on the Worldwide Harmonized Light Vehicle Test Procedure (WLTP) cycle for an average electric vehicle. These improvements increase driving range while lowering total energy consumed. DMD is cost-effective, software-driven and does not require hardware changes to the motor or vehicle. Additionally, DMD avoids many of the rare earth material challenges including escalating future costs, limited supply and sourcing risks.
R. Scott Bailey , president and CEO of Tula Technology, commented, “By 2040, more than half of all passenger vehicles sold globally will be electric*. Tula’s Dynamic Motor Drive technology delivers high-value efficiency improvement to the full spectrum of electrification applications. With DMD, we can take a synchronous reluctance motor with low permanent magnet content and increase its efficiency to a level nearly comparable to a full permanent magnet motor. This reduces reliance on rare earth metals, which translates to lower cost and greater supply chain security. We are very excited about our DMD results, and our team is ready to work with partners and customers to optimize motor system performance in the transportation, industrial and power generation industries.”
Tula’s first product, Dynamic Skip Fire (DSF®), is an advanced cylinder deactivation control strategy that has been shown to significantly reduce CO2 emissions in gasoline engines and has been in production since 2018 with more than one million vehicles on the road. As presented jointly with Cummins at the Society of Automotive Engineers World Congress this year, the diesel application of DSF, Diesel Dynamic Skip Fire (dDSF™), was shown to reduce nitrogen oxide emissions by 74% and CO2 emissions by 5% in a Class 8 truck operating in a low-load cycle. DMD takes Tula’s control strategy to electric motors and has the potential to improve efficiency beyond electric vehicles into other modes of transportation, propulsion, and power conversion.
*Electric Vehicle Outlook 2020, Bloomberg NEF
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 340 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .
Editor’s note: Tula (DMD) video introduces Tula, current electric vehicle motor technology challenges and DMD™ concept, operation and benefits. https://youtu.be/Zx74lfvOZ-U
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
